Greenstone Biosciences

Transforming #drugdiscovery through #genomics #stemcells #AI/ML. Stanford Research Park. Visit:

[Greenstone Biosciences @GreenstoneBio]

To support the important work happening in academic research labs around the world, we continue to offer complimentary human induced pluripotent stem cell (hiPSC) lines (processing and shipping not included) to academic researchers.

Details below ⬇️

[Greenstone Biosciences @GreenstoneBio]

Congratulations to Greenstone Biosciences scientist Ibrahim M. Sayed and co-authors Mey-Sam Chörsi, Stephen N. Jones, Zhenan Bao, and Greenstone Co-Founder Joseph C. Wu on their new Review published in Nature Materials!

Read more here: https://t.co/9oMYkSuGUK

[Greenstone Biosciences @GreenstoneBio]

Today, we are sharing a new resource for cardiovascular research.

In Stem Cell Research, researchers from Stanford University report two patient-derived iPSC lines from individuals diagnosed with TTN-associated DCM.

Read more here: https://t.co/YbijyMDbkE

[Greenstone Biosciences @GreenstoneBio]

New research from Stanford University and Greenstone Biosciences introduces two patient-derived iPSC lines for myotonic dystrophy type 1 (DM1), providing valuable tools to study RNA toxicity, disrupted splicing, and potential therapies.

Read more here: https://t.co/iyFvo2VdmP

[Greenstone Biosciences @GreenstoneBio]

Next Wednesday, October 28, Greenstone Biosciences and Curi Bio will present jointly generated data using a patient-specific iPSC line carrying a heterozygous BAG3 mutation associated with dilated cardiomyopathy.

Register here: https://t.co/saIuM8oNrq

[Greenstone Biosciences @GreenstoneBio]

Todd Herron, Director of our hiPSC BioBank at Greenstone, will be a co-chair for the session “From Bench to Benefit-Cardiac NAMs for Predictive Safety and Efficacy Assessment” on September 23rd at the SPS 2026 Annual Meeting in Montreal.

Read more: https://t.co/HKCemkp5p4

[Greenstone Biosciences @GreenstoneBio]

Greenstone Biosciences has been awarded a Breakthrough T1D Industry Discovery and Development Partnership grant to develop a patient-derived islet cell platform for type 1 diabetes research.

Read the full press release here: https://t.co/rJsQyEpEPT

[Greenstone Biosciences @GreenstoneBio]

In a new article from Drug Target Review, Greenstone Biosciences co-founder Dr. @Joseph_C_Wu discusses how New Approach Methodologies (NAMs) can help close the gap between existing models and human relevance.

Read the full article here: https://t.co/uYf238ZwUV

[Greenstone Biosciences @GreenstoneBio]

Greenstone Biosciences has been awarded a Catalyze R61 grant from the National Heart, Lung, and Blood Institute (NHLBI), part of NIH, to develop new therapeutic approaches for cardiac fibrosis and dilated cardiomyopathy in DMD

Reade more here: https://t.co/noCVvGVlQL

[Greenstone Biosciences @GreenstoneBio]

This week, the U.S. House of Representatives passed the FDA Modernization Act 3.0, an important step in advancing the usage of New Approach Methodologies (NAMs) such as organoids, organ-on-chip systems, and computational models.

Read more here: https://t.co/Yx0NgvonGz

[Greenstone Biosciences @GreenstoneBio]

We are just three weeks out from the next installment of our Greenstone Biosciences webinar series, featuring Dr. Passley Hargrove-Grimes, Program Officer at the National Institutes of Health.

Sign up today: https://t.co/pp08jm2IJh

[Greenstone Biosciences @GreenstoneBio]

Greenstone Biosciences co-founder Dr. @Joseph_C_Wu will be featured in the upcoming documentary “The New Gold Standard,” which explores the science replacing animal testing.

Watch the trailer here: https://t.co/FKkYX0ZSRO

Learn more about Greenstone: https://t.co/RY3Yv0fsHE

[Greenstone Biosciences @GreenstoneBio]

BAG3-associated cardiomyopathy can progress rapidly, but the biology remains difficult to study in conventional models. To help this research, Greenstone Biosciences is now offering 10 patient-derived iPSC lines carrying distinct BAG3 variants

Read more: https://t.co/GJwYYgZ0g5

[Greenstone Biosciences @GreenstoneBio]

PTEN Hamartoma Tumor Syndrome is a rare inherited condition caused by changes in the PTEN gene, and Greenstone Biosciences has contributed to a new paper published in Stem Cell Research that expands tools available to researchers studying it

Read more: https://t.co/s8RI2MLLcP

[Greenstone Biosciences @GreenstoneBio]

The @FDA's push to reduce reliance on animal testing is a call to action for platforms built to replace it. Greenstone Biosciences’ iPSC biobank includes more than 2,500 patient-derived lines of diverse ancestries, ages, and diseases.

Read more here: https://t.co/s1nlhOK5q5

[Greenstone Biosciences @GreenstoneBio]

On June 22, HHS unveiled Operation TrialBlazer, an initiative to accelerate clinical research across the pipeline, from IND submission through late-stage pivotal trials, with a focus on NAMs.

Read more how how these changes will shape the industry here: https://t.co/UsopAXHDbm

[Greenstone Biosciences @GreenstoneBio]

Join tomorrow on Tuesday, June 23rd at 10 AM PST / 1 PM EST for the next installment of Greenstone Bioscience's webinar series, featuring Dr. Weida Tong, Director at the National Center for Toxicological Research (NCTR/FDA).

Sign up here: https://t.co/v5ZU6NZXsK

[Greenstone Biosciences @GreenstoneBio]

Join next week on Tuesday, June 23rd at 10 AM PST / 1 PM EST for the next installment of Greenstone Bioscience's webinar series, featuring Dr. Weida Tong, Director at the National Center for Toxicological Research (NCTR/FDA).

Sign up here: https://t.co/v5ZU6NZXsK

[Greenstone Biosciences @GreenstoneBio]

Join us on Tuesday, June 23rd at 10 AM PST / 1 PM EST for the next installment of Greenstone Bioscience's webinar series, featuring Weida Tong, Director at the National Center for Toxicological Research (NCTR/FDA).

Sign up here: https://t.co/v5ZU6NZXsK

[Greenstone Biosciences @GreenstoneBio]

Join us on Tuesday, June 23rd at 10 AM PST / 1 PM EST for the next installment of Greenstone Bioscience's webinar series, featuring Weida Tong, Director at the National Center for Toxicological Research (NCTR/FDA).

Sign up here: https://t.co/v5ZU6NZXsK

[Greenstone Biosciences @GreenstoneBio]

Greenstone Biosciences is exhibiting at the MPS World Summit 2026, taking place up until May 29th at the Walter E. Washington Convention Center in Washington DC. Find us at Booth #602 to learn about our human iPSC-derived models.

Learn more here: https://t.co/yeu9nekALC